Evidence map›Paper›PMID 42644004›Full record

ArticleFrontiers in medicine2026

Integrated NGS and ddPCR analysis of RAS/RAF mutations in metastatic colorectal cancer among Kazakhstani patients: a pilot study.

Gulmira Kulmambetova, Pavel Tarlykov, Dana Auganova, Alua Gusmaulemova, Botakoz Kurentay, Meiram Mamlin

Abstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gulmira KulmambetovaDepartment of Genomics, National Center for Biotechnology, Astana, Kazakhstan.
Pavel TarlykovDepartment of Genomics, National Center for Biotechnology, Astana, Kazakhstan.
Dana AuganovaDepartment of Genomics, National Center for Biotechnology, Astana, Kazakhstan.
Alua GusmaulemovaDepartment of Genomics, National Center for Biotechnology, Astana, Kazakhstan.
Botakoz KurentayDepartment of Genomics, National Center for Biotechnology, Astana, Kazakhstan.
Meiram MamlinMultidisciplinary Surgery Center, National Research Oncology Center, Astana, Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Colorectal cancer (CRC) is one of the leading causes of cancer-related morbidity and mortality worldwide, and metastatic colorectal cancer (mCRC) is associated with poor prognosis and limited treatment options. Mutations in the Methods: Formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from 30 patients with metastatic colorectal cancer (mCRC), including samples from primary tumors and liver metastases, were analyzed. Genomic DNA was isolated and analyzed for mutation hotspots in the Results: Conclusion:

Indexed as

BRAFcolorectal cancerddPCRKazakhstanKRASmutation

Identifiers

PMID42644004
PMCPMC13504644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.